Logo Image
|Videos|July 4, 2022

Dr. Garmezy on the evolving treatment paradigm for progressive urothelial malignancies

“There has been a ton of activity in recent years with new FDA approvals,” says Benjamin Garmezy, MD.

In this video, Benjamin Garmezy, MD, discusses the expanding armamentarium for the treatment of patients with progressive urothelial malignancies. Garmezy is assistant director of Genitourinary Research at Sarah Cannon Research Institute at Tennessee Oncology.

Related Content

Latest CME

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies
Multimedia

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

View more
Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis
Video

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

View more